BeiGene
ONC
#734
Rank
โ‚ฌ23.16 B
Marketcap
199,35ย โ‚ฌ
Share price
-0.76%
Change (1 day)
62.27%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (ONC) - Total liabilities

Total liabilities on the balance sheet as of December 2024 : โ‚ฌ2.25 Billion

According to BeiGene 's latest financial reports the company's total liabilities are โ‚ฌ2.25 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚ฌ2.48 B21.26%
2023-12-31โ‚ฌ2.05 B10.26%
2022-12-31โ‚ฌ1.86 B-12.31%
2021-12-31โ‚ฌ2.12 B50.72%
2020-12-31โ‚ฌ1.40 B148.76%
2019-12-31โ‚ฌ0.56 B30.51%
2018-12-31โ‚ฌ0.43 B43.62%
2017-12-31โ‚ฌ0.30 B500.24%
2016-12-31โ‚ฌ50.29 M29.57%
2015-12-31โ‚ฌ38.81 M69.51%
2014-12-31โ‚ฌ22.9 M-37.4%
2013-12-31โ‚ฌ36.58 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚ฌ10.57 M-99.53%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.72 B-67.75%๐Ÿ‡บ๐Ÿ‡ธ USA